Vadimezan

Summary

Vadimezan (CHEMBL71263) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 5 conditions including non-small cell lung carcinoma and urothelial carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 15
• Chemistry: 282.29 Da · C17H14O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL71263
Name	Vadimezan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	123964
ChEBI	CHEBI:75934
Molecular formula	C17H14O4
Molecular weight	282.29
InChIKey	XGOYIMQSIKSOBS-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(C=C1)C(=O)C3=CC=CC(=C3O2)CC(=O)O)C

IUPAC name: 2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid

ChEBI definition: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 5,6-dimethyl-9-oxoxanthen-4-yl group.

Pharmacological roles (ChEBI): antineoplastic agent.

Also known as: AS-1404, ASA-404, ASA404, DMXAA, NSC-640488, Vadimezan, SID29217541, SID174006683, VADIMEZAN, DMXAA (VADIMEZAN), DMXAA (Vadimezan)

Patent coverage: 1,768 distinct patent families (5,161 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Alpha-galactosidase A, Stimulator of interferon genes protein, Stimulator of interferon genes protein.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q3TBT3	6.89	Kd	130	nM	CHEMBL_ACT_19004323
Q3TBT3	6.89	Kd	130	nM	CHEMBL_ACT_19125353
Q3TBT3	6.15	Kd	710	nM	CHEMBL_ACT_24734155
Q3TBT3	5.92	IC50	1200	nM	CHEMBL_ACT_24408560

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
lung neoplasm	2	MONDO:0021117	MONDO:0008903
neoplasm	1	MONDO:0005070	EFO:0000616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE1	11
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00662597	PHASE3	TERMINATED	ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00738387	PHASE3	TERMINATED	A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
NCT01057342	PHASE2	COMPLETED	Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT01071928	PHASE2	WITHDRAWN	Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
NCT00003697	PHASE1	COMPLETED	Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors
NCT00674102	PHASE1	COMPLETED	An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT00856336	PHASE1	COMPLETED	Phase I Safety Study of DMXAA in Refractory Tumors
NCT00863733	PHASE1	COMPLETED	Study of DMXAA (Now Known as ASA404) in Solid Tumors
NCT01031212	PHASE1	WITHDRAWN	ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
NCT01240642	PHASE1	TERMINATED	An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
NCT01278758	PHASE1	TERMINATED	A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
NCT01278849	PHASE1	TERMINATED	An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
NCT01285453	PHASE1	COMPLETED	Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
NCT01290380	PHASE1	TERMINATED	A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
NCT01299701	PHASE1	TERMINATED	A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).